MedPath

Surgical Techniques in Diabetes Mellitus-II and Obesity. Metabolic Surgery Study (MSS)

Not Applicable
Conditions
Diabetes Mellitus
Obesity
Interventions
Procedure: Modified gastric bypass.
Procedure: Gastric bypass
Procedure: Slevee Gastrectomy
Registration Number
NCT02310555
Lead Sponsor
Hospital Universitario Virgen de la Arrixaca
Brief Summary

The aim of this study is to compare clinical and laboratory findings of three surgical techniques in metabolic surgery in patients with type II diabetes mellitus and obesity (BMI\> 30).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • BMI 30-40
  • Diabetes Mellitus type II less than 10 years of evolution.
  • Anti-GAD, anti-pancreatic islets negative antibodies.
  • C peptide normally between 0.9 and 4.
  • Glycosylated hemoglobin greater than 6.5%.
  • Less than 5 years of use insulin.
Exclusion Criteria
  • Cirrosis hepática.
  • coagulopathies.
  • Type 1 diabetes.
  • HIV positive.
  • Stomach or small intestine previous surgeries .
  • Diseases of the exocrine pancreas: pancreatitis, pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis.
  • Endocrinopathies: acromegaly, glucagonoma, Cushing's syndrome, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma.
  • Genetic syndromes with diabetes.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Modified gastric bypass.Modified gastric bypass.Modified gastric bypass. Resection body and fundus gastric
Gastric bypassGastric bypassclassic Gastric bypass
Slevee GastrectomySlevee GastrectomySlevee Gastrectomy
Primary Outcome Measures
NameTimeMethod
Remission diabetes mellitus type IIDurign two years

1. Partial remission: Not diagnostic of DM HbA1c (\<6.5%); Basal glucose 100-125 mg / dl (5.6-6.9 mmol / l); Absence of drug treatment; At least one year.

2. Complete remission: Normal HbA1c (\<6%); basal glucose \<100 mg / dl (\<5.6 mmol / l); Absence of drug treatment; At least one year.

3. Prolonged remission: At least 5 years of remission.

4. Improvement: HbA1c \<7% with pharmacological treatment.

Secondary Outcome Measures
NameTimeMethod
Adverse effects in the short termDuring three months since surgery

We'll measure the number of patients with postoperative complications and the the degree of severity of Clavien- Dindo Classification

Adverse effects in the long termSince third month after surgery untiil two years

We'll measure the number of patients with postoperative complications and the the degree of severity of Clavien- Dindo Classification

Weight lossDuring two years

Trial Locations

Locations (1)

Hospital Clínico Universitario Virgen de la Arrixaca

🇪🇸

El Palmar., Murcia, Spain

© Copyright 2025. All Rights Reserved by MedPath